Autopsy report · NCT03269695
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
Cause of deathFunding or business
“The Sponsor changed R\&D strategy and priority.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 3 years 1 month before it stopped.
- 20 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Ulcerative Colitis
- Interventions
- PF-06687234; Placebo
- Participants
- 20
- Sites
- 34
- Countries
- Australia, Belgium, Germany, Israel, Italy, Saudi Arabia, Serbia, South Korea, Turkey (Türkiye), United States
Trials that died the same way
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
“The sponsor has adjusted its R\&D strategy.” - Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
“The sponsor's R\&D strategy is adjusted.” - A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
“Sponsor's R\&D strategy adjusted.” - A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
“Sponsor R \& D Strategy Adjustment” - Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
“Strategic direction of the sponsor changed”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.